{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T06:28:30Z","timestamp":1775024910146,"version":"3.50.1"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The immune landscape of renal cell carcinoma (RCC) is a key determinant of response to immune checkpoint inhibitors (ICIs). Yet, direct comparisons of immune infiltrates across histologic subtypes and metastatic sites within the same patient are rarely possible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical case<\/jats:title>\n                    <jats:p>A 71-year-old man underwent left-sided nephrectomy for clear cell RCC (ccRCC) in 2013. He developed a right-sided renal and liver-capsule lesion in 2024, with an enlarged paracaval lymph node. Partial right-sided nephrectomy, liver resection, and lymphadenectomy confirmed RCC with prominent sarcomatoid histology (sRCC). Chest CT and pelvic MRI scan did not detect metastases, but the cervical spine was not explored due to lack of symptoms. Two cycles of nivolumab plus ipilimumab were performed before discovering severe cervical spine pain. MRI identified a previously missed metastasis to the C4 vertebral body. Corpectomy achieved nearly complete tumor resection supplemented with fusion. Immunohistochemistry and multiplex immunofluorescence for PD-L1\/CD3\/CD20\/CD163\/C5aR1\/CD31\/CA9 were performed on primary tumors and metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Here we show (1) robust CD3\n                      <jats:sup>+<\/jats:sup>\n                      and CD20\n                      <jats:sup>+<\/jats:sup>\n                      infiltration in primary tumors and metastases, with immune cells in direct contact with tumor cells or organized in lymphoid aggregates\/tertiary lymphoid structures; (2) PD-L1 overexpression in sRCC and nodal metastasis but absent in post-immunotherapy bone lesions; (3) increased CD163\n                      <jats:sup>+<\/jats:sup>\n                      macrophages in sRCC and metastases versus ccRCC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case illustrates that ICIs can induce near-complete eradication of bone metastases; that bone is not an immune-exempt organ, with massive intratumoral immune cell infiltration; and that immediate immune-mediated tumor clearance prevents structural skeletal damage, which merits careful surveillance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1785561","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:27:50Z","timestamp":1775017670000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Metachronous bilateral renal cancer with immune checkpoint blockade-mediated eradication of bone metastasis: case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Dimitar","family":"Metodiev","sequence":"first","affiliation":[{"name":"Clinical Pathology Laboratory, MHAT \u201cNadezda\u201d Women\u2019s Health Hospital","place":["Sofia, Bulgaria"]},{"name":"Neuropathological Laboratory, St. Ivan Rilski University Hospital","place":["Sofia, Bulgaria"]},{"name":"Department of General and Clinical Pathology, Faculty of Medicine, Medical University of Sofia","place":["Sofia, Bulgaria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsvetan","family":"Borisov","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, Medical University of Sofia","place":["Sofia, Bulgaria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Alexis","family":"Da Costa","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Sorbonne Universit\u00e9, Universit\u00e9 de Paris Cit\u00e9, Team Inflammation, Complement and Cancer","place":["Paris, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaeddine","family":"Redissi","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Sorbonne Universit\u00e9, Universit\u00e9 de Paris Cit\u00e9, Team Inflammation, Complement and Cancer","place":["Paris, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Cremer","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Sorbonne Universit\u00e9, Universit\u00e9 de Paris Cit\u00e9, Team Inflammation, Complement and Cancer","place":["Paris, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mila","family":"Petrova","sequence":"additional","affiliation":[{"name":"Oncology Department, MHAT \u201cNadezda\u201d Women\u2019s Health Hospital","place":["Sofia, Bulgaria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yann A.","family":"Vano","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Sorbonne Universit\u00e9, Universit\u00e9 de Paris Cit\u00e9, Team Inflammation, Complement and Cancer","place":["Paris, France"]},{"name":"Oncology Department, Foch Hospital","place":["Suresnes, France"]},{"name":"Versailles St Quentin University","place":["Paris, France"]},{"name":"University Hospital Federation (FHU) COMET","place":["Paris, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubka T.","family":"Roumenina","sequence":"additional","affiliation":[{"name":"Centre de Recherche des Cordeliers, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Sorbonne Universit\u00e9, Universit\u00e9 de Paris Cit\u00e9, Team Inflammation, Complement and Cancer","place":["Paris, France"]},{"name":"University Hospital Federation (FHU) COMET","place":["Paris, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilyan","family":"Ferdinandov","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, Medical University of Sofia","place":["Sofia, Bulgaria"]},{"name":"Clinic of Neurosurgery, St Ivan Rilski University Hospital","place":["Sofia, Bulgaria"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-020-00382-9","article-title":"Sarcomatoid renal cell carcinoma: biology, natural history and management","volume":"17","author":"Blum","year":"2020","journal-title":"Nat Rev Urol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"e009495","DOI":"10.1136\/jitc-2024-009495","article-title":"Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214","volume":"12","author":"Mantia","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat Commun"},{"key":"B4","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejca.2020.06.008","article-title":"Patients with sarcomatoid renal cell carcinoma - re-defining the first-line of treatment: A meta-analysis of randomized clinical trials with immune checkpoint inhibitors","volume":"136","author":"Iacovelli","year":"2020","journal-title":"Eur J Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00832-3","article-title":"A multi-institutional, retrospective analysis of patients with metastatic renal cell carcinoma to bone treated with combination ipilimumab and nivolumab","volume":"16","author":"Desai","year":"2021","journal-title":"Target Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.21873\/cdp.10252","article-title":"Bone metastases in renal cell carcinoma: Impact of immunotherapy on survival","volume":"3","author":"Gambale","year":"2023","journal-title":"Cancer Diagn Progn"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2023.100505","article-title":"Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms","volume":"43","author":"Joseph","year":"2023","journal-title":"J Bone Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8970173","article-title":"Immune checkpoint inhibitor therapy for bone metastases: Specific microenvironment and current situation","volume":"2021","author":"Liu","year":"2021","journal-title":"J Immunol Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-4962940\/v1","article-title":"Efficacy of second-line nivolumab versus tyrosine kinase inhibitors for renal cell carcinoma with bone metastases","volume":"45","author":"Yamamichi","year":"2025","journal-title":"Anticancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.980456","article-title":"Case report: Complete remission of bone metastasis from renal cell carcinoma in histopathological examination after treatment with immune checkpoint inhibitors","volume":"13","author":"Asano","year":"2022","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00128-0","article-title":"Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomized, phase 2 trial","volume":"23","author":"Vano","year":"2022","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-017-0262-y","article-title":"Distribution of vascular patterns in different subtypes of renal cell carcinoma. A morphometric study in two distinct types of blood vessels","volume":"24","author":"Ruiz-Sauri","year":"2018","journal-title":"Pathol Oncol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/2025.03.27.645644","article-title":"3D vascularized microtumors unveil aberrant ccRCC vasculature and differential sensitivity to targeted treatments","author":"Brassard-Jollive","year":"2025","journal-title":"Biorxive"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.01.122","article-title":"Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval","volume":"177","author":"Klatte","year":"2007","journal-title":"J Urol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13256-024-04527-x","article-title":"Detection of two synchronous histologically different renal cell carcinoma subtypes in the same kidney: a case report and review of the literature","volume":"18","author":"Sakr","year":"2024","journal-title":"J Med Case Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.659706","article-title":"Case report: Bilateral renal cell carcinoma with different histological and morphological features, clear cell and cystic thyroid-like follicular subtype","volume":"11","author":"Ni","year":"2021","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.urolonc.2015.04.011","article-title":"Percentage of sarcomatoid component as a prognostic indicator for survival in renal cell carcinoma with sarcomatoid dedifferentiation","volume":"33","author":"Adibi","year":"2015","journal-title":"Urol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2013.04.026","article-title":"Prognostic effect of sarcomatoid dedifferentiation in patients with surgically treated renal cell carcinoma: a matched-pair analysis","volume":"11","author":"Brookman-May","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.12.001","article-title":"Using percentage of sarcomatoid differentiation as a prognostic factor in renal cell carcinoma","volume":"13","author":"Kim","year":"2015","journal-title":"Clin Genitourin Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12781","article-title":"A novel prognostic model for patients with sarcomatoid renal cell carcinoma","volume":"115","author":"Zhang","year":"2015","journal-title":"BJU Int"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-20-2063","article-title":"Efficacy and safety of nivolumab plus ipilimumab versus sunitinib for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume-title":"Clin Cancer Res.","author":"Tannir","year":"2021"},{"key":"B23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2025.101950","article-title":"Complement and the hallmarks of cancer","volume":"78","author":"Artero","year":"2025","journal-title":"Semin Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"185\u201394","DOI":"10.1038\/s41416-025-03260-6","article-title":"Complement system in tumor growth and metastases","volume":"134","author":"Borisov","year":"2025","journal-title":"Br J Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/cas.12314","article-title":"Clinical significance of macrophage heterogeneity in human Malignant tumors","volume":"105","author":"Komohara","year":"2014","journal-title":"Cancer Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/0952-7915(90)90031-b","article-title":"Tumor-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.08.009","article-title":"Tertiary lymphoid structures and B cells: An intratumoral immunity cycle","volume":"56","author":"Fridman","year":"2023","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S1561","DOI":"10.1016\/j.annonc.2023.10.356","article-title":"Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma","volume":"34","author":"Xu","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e006773","DOI":"10.1136\/jitc-2023-006773","article-title":"Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop","volume":"11","author":"Clifton","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41698-024-00671-1","article-title":"The current landscape of spatial biomarkers for prediction of response to immune checkpoint inhibition","volume":"8","author":"Williams","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.03.036","article-title":"Bone metastases diminish extraosseous response to checkpoint blockade immunotherapy through osteopontin-producing osteoclasts","volume":"43","author":"Cheng","year":"2025","journal-title":"Cancer Cell"},{"key":"B34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.4541","article-title":"Neoadjuvant lenvatinib plus pembrolizumab for resectable clear-cell renal cell carcinoma (PELUR): A prospective phase 2 study","volume-title":"J Clin Oncol","author":"Zhu","year":"2025"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.4509","article-title":"Exploratory analysis from NEOAVAX, a neoadjuvant trial of avelumab\/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy","volume-title":"J Clin Oncol","author":"Bex","year":"2025"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1785561\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T04:28:04Z","timestamp":1775017684000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1785561\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":35,"alternative-id":["10.3389\/fonc.2026.1785561"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1785561","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"article-number":"1785561"}}